
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
As a sponsor of CME, Contemporary Pediatrics understands its responsibility to make CME relevant to the practicing pediatrician.






